Table 3 Topics receiving highest priority rankings for funded comparative Effectiveness Systematic Reviews in CKD
From: Setting an agenda for comparative effectiveness systematic reviews in CKD care
Topic | CKD Area | Rank* | Feasibility | |||
|---|---|---|---|---|---|---|
Systematic reviews | **Randomized controlled trials | |||||
Pharmacologic | Behavioral | †Priority population | ||||
Proteinuria | Progression | 1 | 9 | >100 | 20 | 0 |
Access to care | Progression | 2 | 1 | 2 | 2 | 2 |
Hypertension | Progression | 2 | 11 | 68 | 3 | 37 |
Screening benefits and harms | Detection | 3 | 1 | 0 | 0 | 0 |
Hypertension control | Prevention | 4 | 0 | 1 | 0 | 0 |
Patient knowledge/education | Prevention | 5 | 0 | 0 | 3 | 3 |
Diabetes control and prevention | Prevention | 6 | 2 | 18 | 3 | 23 |
Cardiovascular Disease | Complications | 7 | 3 | 40 | 0 | 5 |
Patient safety | Progression | 7 | 5 | 64 | 2 | 4 |
Health Information Technology | Progression | 8 | 0 | 5 | 1 | 0 |
Patient Safety | Prevention | 9 | 24 | 29 | 0 | 3 |
Vitamin D | Prevention | 10 | 0 | 7 | 0 | 7 |
Classification | Detection | 11 | 4 | 0 | 0 | ‡10 |
Obesity/Weight Management | Prevention | 12 | 0 | 0 | 5 | 1 |
Dietary strategies | Progression | 12 | 11 | 0 | 13 | 3 |
Inflammation | Progression | 12 | 2 | 21 | 0 | 5 |
Collaboration strategies | Progression | 12 | 0 | 0 | 2 | 1 |
Metabolic acidosis | Progression | 12 | 0 | 4 | 0 | 0 |